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Background: Implant-based breast reconstruction (IBBR) is themost commonly performed reconstruct-
ive procedure and its economic impact is significant. This study aimed to analyse whether a direct
one-stage IBBR with use of an acellular dermal matrix (ADM) is more cost-effective than two-stage
(expander-implant) breast reconstruction.
Methods: The BRIOS (Breast Reconstruction In One Stage) study was an open-label multicentre
RCT in which women scheduled for skin-sparing mastectomy and immediate IBBR were randomized
between one-stage IBBR with ADM or two-stage IBBR. Duration of surgery and hospital stay, and visits
for the primary surgery, unplanned and cosmetic procedures were recorded. Costs were estimated
at an institutional level. Health status was assessed by means of the EuroQol Five Dimensions 5L
questionnaire.
Results: Fifty-nine patients (91 breasts) underwent one-stage IBBR with ADM and 62 patients (92
breasts) two-stage IBBR. The mean(s.d.) duration of surgery in the one-stage group was significantly
longer than that for two-stage IBBR for unilateral (2⋅52(0⋅55) versus 2⋅02(0⋅35) h; P<0⋅001) and bilateral
(4⋅03(1⋅00) versus 3⋅25(0⋅58) h; P= 0⋅017) reconstructions. Costs were higher for one-stage compared
with two-stage IBBR for both unilateral (€12 448 (95 per cent c.i. 10 722 to 14 387) versus €9871 (9373 to
10 445) respectively; P= 0⋅025) and bilateral (€16 939 (14 887 to 19 360) versus €13383 (12 414 to 14 669);
P= 0⋅002) reconstructions. This was partly related to the use of relatively expensive ADM. There was no
difference in postoperative health status between the groups.
Conclusion: One-stage IBBR with ADM was associated with higher costs, but similar health
status, compared with conventional two-stage IBBR. Registration number: NTR5446 (http://www
.trialregister.nl).
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Introduction
Worldwide, breast cancer is the most common cancer
in women, and its global societal and economic bur-
den is enormous1,2. Improving treatment outcomes while
controlling costs is a fundamental challenge faced by all
healthcare systems3. In Western countries, the 5-year sur-
vival rate of women diagnosed with breast cancer is approx-
imately 90 per cent4,5. Currently, there are more than 3⋅1
million breast cancer survivors in the USA alone4. Over
60 000 new cases of in situ breast carcinoma are expected
to be diagnosed among women in 2017 in the USA6,
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indicating that the number of breast cancer survivors will
increase progressively. More than 90 per cent of women
receive surgical treatment, consisting of either lumpectomy
or mastectomy5. Today, breast reconstruction is offered as a
standard treatment option after mastectomy in most devel-
oped countries, with the aim of improving long-term out-
comes and quality of life. As up to 20 per cent of women
undergo breast reconstruction after a mastectomy, it is one
of most common reconstructive procedures undertaken by
plastic surgeons7. An increase in immediate reconstruc-
tions has also been noted8.
There are many surgical options for breast reconstruc-
tion, but it is not known which is most cost-effective for
an individual patient. Implant-based breast reconstruction
(IBBR) methods are used in approximately 80 per cent
of reconstructions following mastectomy9. IBBR is per-
formed either in one or two stages, with or without the use
of an additional tissue matrix. It has been suggested that
one-stage reconstruction augmented with an acellular der-
mal matrix (ADM) is more cost-effective than two-stage
IBBR. Having only a single procedure and insertion of a
larger breast implant because of enlargement of the sub-
pectoral pocket are advantages of one-stage ADM-assisted
IBBR. Improved aesthetic outcome with use of an ADM
has been reported as an additional advantage. Several
studies10–14 that compared the cost-effectiveness of dif-
ferent IBBR methods or IBBR with autologous recon-
structions have reported conflicting data. In general, the
additional use of an ADM was considered cost-effective.
In most studies, however, a decision analytical model
was used, in which clinical outcomes based on previously
published literature were incorporated in the analyses with
various probabilities11,12,14,15. This method risks selection
bias, as clinical outcomes after breast reconstruction vary
considerably, with complication rates ranging from 4 to 50
per cent16–20.
The prospective randomized BRIOS (Breast Reconstruc-
tion In One Stage) study compared the cost-effectiveness
of one-stage ADM-assisted IBBR and two-stage expander-
implant breast reconstruction. The BRIOS study was an
open-label phase IV multicentre RCT performed in eight
hospitals in the Netherlands21,22.
Methods
The BRIOS study was a prospective multicentre RCT.
Eligible women were older than 18 years with breast
carcinoma or a gene mutation linked to breast cancer,
who intended to undergo skin-sparing mastectomy and
immediate IBBR. Women were assigned randomly to
undergo one-stage IBBR with ADM or two-stage IBBR.
The objective was to compare outcomes of one-stage
IBBR combined with ADM (Strattice™; LifeCell,
Branchburg, New Jersey, USA) with outcomes of con-
ventional two-stage tissue expander-implant breast
reconstruction. The primary endpoint of the BRIOS
study was health-related quality of life assessed using
the BREAST-Q at 1 year after placement of the def-
inite implant. The study was open label, and surgeons
and patients were informed about the allocated treat-
ment at least 3 days before surgery. The full study
design, methodology and surgical techniques have been
described previously21,22. The secondary outcome of
cost-effectiveness is reported here.
The protocol was approved by the institutional review
board from each study centre and the study was prereg-
istered in the Netherlands Trial Register (NTR5446). All
patients provided written informed consent. The BRIOS
study was performed in accordance with the Declaration of
Helsinki, the Consort Statement23 and guidelines for good
clinical practice.
Outcome measures
The following data were recorded: duration of surgery,
duration of hospital stay, number of outpatient visits
for expander fill in patients who had a two-stage pro-
cedure, and number of additional outpatient visits if a
complication occurred. These data were collected for the
primary breast reconstruction procedure, for the oper-
ations needed to treat surgical complications, and for
secondary reconstructions if an implant was removed. The
duration of surgery was defined as the time from first
incision to closure of the wound. All planned second-stage
procedures were completed.
Cost calculation
Direct costs were calculated, including all expenses listed
in Table 1. First, costs of the primary procedures only
were calculated. Subsequently, costs of breast reconstruc-
tion including operations for surgical complications and
secondary procedures were included. Costs associated with
procedures for cosmetic improvements were also calculated
in a separate analysis. The analyses were performed sep-
arately for unilateral and bilateral reconstructions. Costs
were estimated in euros based on cost statements from
the financial department of VU University Medical Cen-
tre (Amsterdam, the Netherlands). An overview of costs
used in the calculations is shown in Table 1. The operation
room (OR) costs included materials, OR and anaesthesia
care team and cleaning of the OR. The surgeon’s fee and
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Table 1 Costs used for the analysis
Cost (€)
Hospital visits
First outpatient visit 130
Regular outpatient visit (including visits
for expander inflation)
70
Surgery (per h)* 1240
Surgeon’s fee (per h) 150
Hospital admission
Day-care patient 400
Inpatient (per day) 550
Materials
Tissue expander 530
Breast prosthesis 530
ADM (Strattice®) 2370
*Including all materials, operating room and anaesthesia care team, and
cleaning of operating room, but excluding surgeon’s fee. ADM, acellular
dermal matrix.
costs of the implants (tissue expander, breast prosthesis and
ADM) were calculated separately. Calculation of the costs
was based on a single surgeon performing each operation.
Patient-reported outcomes
Patient-reported outcomes were measured using the Euro-
Qol Five Dimensions 5L questionnaire (EQ-5D-5L™;
EuroQol Group, Rotterdam, the Netherlands), a stand-
ardized measure of health status, assessing the follow-
ing five dimensions: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. Each domain has
five levels: no problems (score 1), slight problems (2), mod-
erate problems (3), severe problems (4) and extreme prob-
lems (5). Answers were converted into index values using
the SPSS® (IBM, Armonk, New York, USA) syntax file
that can be ordered from the EuroQol office, enabling
comparison of these results with the reference values24.
Self-rated health was measured on a visual analogue scale,
the EQ-VAS, using a 20-cm vertical line with scores
ranging from 0 (worst health you can imagine) to 100 (best
health you can imagine).
Statistical analysis
Descriptive statistics were used for all variables. Differ-
ences between groups in duration of surgery and num-
ber of hospital visits in the event of complication were
assessed by means of Student’s t tests. Mann–Whitney
U tests were used to evaluate differences in hospital stay.
Bootstrap analysis was used to calculate 95 per cent confi-
dence interval for the costs. The significance of differences
in costs, EQ-5D-5L™ index values and EQ-VAS scores
was assessed using the Student’s t test.
Results
Of 142 women enrolled and randomized, 59 who had
one-stage IBBR with ADM and 62 who underwent
two-stage IBBR were included in the analysis (Fig. 1).
Comprehensive details of patient demographics were
published previously21. Mean follow-up after the first
operation was 37 months for one-stage IBBR with ADM
and 35 months for two-stage IBBR. Significantly more
complications occurred in the one-stage group (40 versus
14 per cent of reconstructions), which resulted in higher
reoperation (32 versus 13 per cent) and implant removal
(26 versus 4 per cent) rates (Table 2)21.
Primary breast reconstruction procedure
The primary surgery took significantly longer
for one-stage IBBR with ADM than two-stage recon-
struction, for both unilateral (mean(s.d.) 172(55) versus
122(35) min respectively; P< 0⋅001) and bilateral (243(60)
versus 205(58) min; P= 0⋅017) reconstructions (Table 3).
Duration of hospital stay after the primary operation did
not differ significantly between the two groups. Combin-
ing the two operations in the two-stage group, the total
operating time for bilateral two-stage reconstructions
was longer than that for bilateral one-stage reconstruc-
tion (289(71) versus 243(60) min; P= 0⋅013). The total
median hospital stay was longer for unilateral and bilateral
two-stage reconstructions than for one-stage reconstruc-
tions (unilateral: median 5 (range 3–10) versus 3 (2–8) days
respectively, P= 0⋅002; bilateral: 5 (2–11) versus 4 (2–11)
days; P= 0⋅008).
The mean total direct cost for unilateral one-stage IBBR
was comparable to that of unilateral two-stage reconstruc-
tion (€9052 (95 per cent c.i. 8409 to 9815) versus €8940
(8445 to 9537) respectively; P= 0⋅815). However, for bilat-
eral reconstruction, the cost of one-stage IBBR was higher
than that of two-stage reconstruction (€14 364 (13 672 to
15 088) versus €12 566 (11 790 to 13 471); P= 0⋅004), owing
to higher implant costs in the one-stage group.
Additional procedures owing to surgical
complications
Among patients who had a complication, visits to the out-
patient clinic were more frequent after one-stage than
two-stage reconstruction. This difference was statistic-
ally significant for bilateral reconstructions (mean(s.d.)
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 586–595
on behalf of BJS Society Ltd.
Cost-effectiveness of acellular dermal matrix in implant-based breast reconstruction 589
Fig. 1 Flow diagram for the trial
Patients enrolled
n=142
Assigned to undergo
two-stage IBBR
n=73
Underwent first-stage
surgery
n=63*
Underwent surgery
n=61
Excluded n=8
 Declined treatment n=3
 Not operated according to
 protocol n=5
Excluded n=2
 Not treated according to
 randomization n=1†
 Withdrew from study n=1
Included in analyses
n=62
Included in analyses
n=59
Excluded n=11
 Died n=1
 Declined treatment n=8
 Not operated according to
 protocol n=2
Underwent second-stage surgery n=59
Did not undergo second-stage surgery n=4
 Excluded (withdrew from study) n=1
 Did not receive second operation n=1†
 Went on to other treatment n=1†
 Died n=1†
Assigned to undergo
one-stage IBBR with ADM
n=69
*The patient underwent two-stage implant-based breast reconstruction (IBBR) because of the surgeon’s intraoperative decision, and was included in the
two-stage group for analysis. †Included in final analysis. ADM, acellular dermal matrix.
6⋅00(3⋅30) versus 2⋅67(2⋅73); P = 0⋅042) (Table 4; Table S1,
supporting information).
In the one-stage group, nine patients with unilateral
reconstructions and 13 with bilateral reconstructions
underwent one or more reoperations. In the two-stage
group, three and five patients respectively had one or more
reoperations (Table 4).
Most reconstructions in patients with a failed unilateral
procedure were converted to an autologous reconstruction
(4 in the 1-stage group, 2 in 2-stage group). In patients
with a failed bilateral reconstruction, salvage was achieved
with either an implant reconstruction or combination of an
implant and autologous tissue (Table S2, supporting infor-
mation). Additional implant materials needed for recon-
struction were tissue expanders (18 in 1-stage group, 1 in
2-stage group), breast implants (17 and 1 respectively) and
another ADM (1-stage group). In the unilateral two-stage
group, two tissue expanders were replaced by autologous
flaps (Table 4).
Combining costs, including those for complication-
related and salvage procedures, the mean costs per patient
were higher in the one-stage group compared with the
two-stage group for both unilateral (€11 752 (95 per
cent c.i. 9987 to 13 611) versus €9000 (8551 to 9479)
respectively; P= 0⋅008) and bilateral (€16 714 (14 909
to 18 971) versus €13 061 (12 039 to 14 233); P= 0⋅001)
reconstructions.
Additional procedures not related to surgical
complications
During exchange of the tissue expander for the def-
inite implant, a secondary correction was performed in 19
breasts (17 patients) in the unilateral group, and 20 recon-
structions (12 patients) in the bilateral group. Secondary
revisional surgery was undertaken in 12 breasts (8 patients)
in the unilateral one-stage group, nine breasts (9 patients)
in the unilateral two-stage group, six breasts (4 patients)
in the bilateral one-stage group and 13 breasts (7 patients)
in the bilateral two-stage group (Table 5).
Including costs for cosmetic procedures, the overall
direct costs were higher in the one-stage compared with
the two-stage group for both unilateral (€12 448 (95 per
cent c.i. 10 722 to 14 387) versus €9871 (9373 to 10 445)
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Table 2 Surgical complications, reoperations and removal of implant
Unilateral Bilateral
One-stage
IBBR+ADM
(n= 27 patients)
Two-stage
IBBR
(n=32 patients)
One-stage IBBR+ADM
(n=32 patients;
64 reconstructions)
Two-stage IBBR
(n= 30 patients;
60 reconstructions)
Surgical complications 12 (44) 4 (13) 24 (38) [16 patients] 9 (15) [7 patients]
Haematoma 2 (7) 1 (3) 1 (2) 1 (2)
Seroma 0 (0) 0 (0) 0 (0) 2 (2)
Burn wound 0 (0) 0 (0) 0 (0) 1 (2)
Blister 0 (0) 0 (0) 0 (0) 1 (2)
Redness without signs of infection 3 (11) 1 (3) 2 (3) 0 (0)
Wound infection 1 (4) 1 (3) 8 (13) 1 (2)
Skin necrosis 3 (11) 0 (0) 8 (13) 1 (2)
Wound dehiscence: exposure
ADM 3 (11) – 2 (3) –
ADM and implant 0 (0) – 2 (3) –
Unknown 0 (0) 0 (0) 1 (2) 0 (0)
Suspected perforation of expander – 1 (3) – 1 (2)
Pain, capsular contracture 0 (0) 0 (0) 0 (0) 1 (2)
Reoperations
Haematoma evacuation 2 (11) 1 (3) 1 (2) 3 (5)
Excision of burn wound 0 (0) 0 (0) 0 (0) 1 (2)
Botulinum toxin injection 0 (0) 1 (3) 1 (0) 0 (0)
Necrosectomy 0 (0) 0 (0) 1 (2) 1 (2)
Removal of
Tissue expander – 2 (6) – 1 (2)
Implant 1 (4) 0 (0) 9 (14) 1 (2)
ADM 0 (0) – 2 (3) –
ADM+ implant 5 (19) – 7 (11) –
Change of implant (owing to capsular
contracture)
0 (0) 0 (0) 0 (0) 1 (2)
Values in parentheses are percentage of breasts. IBBR, implant-based breast reconstruction; ADM, acellular dermal matrix.
Table 3 Operation details for both primary breast reconstructive procedures (per patient)
Unilateral Bilateral
One-stage IBBR+ADM
(n=27)
Two-stage IBBR
(n= 32) P‡
One-stage IBBR+ADM
(n=32)
Two-stage IBBR
(n= 30) P‡
Duration of operation (min)*
First operation 172(55) (n=25) 122(35) (n =30) <0⋅001 243(60) 205(58) (n= 29) 0⋅017
Second operation – 62(40) (n= 30) – 71(33) (n= 22)
Overall 172(55) 189(55) 0⋅298 243(60) 289(71) 0⋅013
Duration of hospital stay (days)†
First operation 3 (2–8) 3 (2–8) 4 (2–11) 3 (2–6)
Second operation – 2 (1–4) – 2 (1–3) (n= 28)
Overall 3 (2–8) 5⋅0 (3–10) 0⋅002§ 4 (2–11) 5 (2–11) 0⋅008§
No. of expander fillings* – 5⋅27(2⋅55) – 6⋅17(2⋅55) (n= 29)
Values are *mean(s.d.) and †median (range). IBBR, implant-based breast reconstruction; ADM, acellular dermal matrix. ‡Student’s t test, except
§Mann–Whitney U test.
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Table 4 Additional operation details for both breast reconstructive procedures in patients with complications (per patient)
Unilateral Bilateral
One-stage IBBR+ADM
(n= 10)
Two-stage IBBR
(n= 4)
One-stage IBBR+ADM
(n= 15)
Two-stage IBBR
(n= 6)
No. of additional outpatient visits 3⋅10(1⋅85) 2⋅75(2⋅22) 6⋅00(3⋅30) 2⋅67(2⋅73)
No. of patients requiring additional
operation(s)
9 3 13 5
No. of additional reoperations 2⋅0(0⋅50) 2⋅00(2⋅65) 2⋅92(1⋅19) 1⋅00
Additional operating time (min) 79(102) 134(134) 60(21) 45(17)
Additional duration of hospital stay (days) 3⋅63(2⋅96) 4⋅83(2⋅32) 2⋅51(1⋅52) 3⋅00(2⋅83)
Additional materials Expander 2 Expander 16 Expander 1
Implant 2 Implant 15 Implant 1
Other ADM 1
*Values are mean(s.d.). IBBR, implant-based breast reconstruction; ADM, acellular dermal matrix.
Table 5 Additional procedures not directly related to surgical complications
Unilateral Bilateral
One-stage
IBBR+ADM
(n= 27 patients)*
Two-stage
IBBR
(n=32 patients)*
One-stage
IBBR+ADM
(n=32 patients;
64 reconstructions)†
Two-stage IBBR
(n=30 patients;
60 reconstructions)†
Corrections during second operation 0 (0) 17 (53) [19 reconstructions] 0 (0) 20 (33) [12 patients]
Scarification of capsule 0 (0) 1 (3) 0 (0) 0 (0)
Lipofilling 0 (0) 2 (6) 0 (0) 5 (8) [3 patients]
Capsulotomy or capsulectomy 0 (0) 3 (9) 0 (0) 13 (22) [7 patients]
Contralateral/unilateral symmetrization‡ 0 (0) 6 (19) 0 (0) 1 (2) [1 patient]
Combination§ 0 (0) 5 (16) [7 breasts] 0 (0) 11 (2) [1 patient]
Secondary revision surgery 8 (30) [12 reconstructions] 9 (28) 6 (9) [4 patients] 13 (22) [7 patients]
Redundant tissue¶ 0 (0) 1 (3) 1 (2) 4 (7) [2 patients]
Layer thickness# 2 (7) 1 (3) 3 (5) [2 patients] 0 (0)
Position of implant** 2 (7) 4 (13) 0 (0) 5 (8) [3 patients]
Contralateral preventive mastectomy 0 (0) 1 (3) 0 (0) 0 (0)
Combination†† 4 (15) [8 reconstructions] 2 (6) 2 (3) [1 patient] 4 (7) [2 patients]
Values in parentheses are percentage of *patients and †breasts. ‡Contralateral symmetrization reduction mammoplasty or augmentation. §Combination of
other procedures (scarification of capsule, capsulotomy or capsulectomy or lipofilling). ¶Dog-ear correction and scar revision. #Lipofilling. **Lowering of
inframammary fold, new implant, contralateral symmetrization reduction mammoplasty or augmentation. ††Combination of other procedures (redundant
tissue, layer thickness or position of implant).
Table 6 Health status measured using EQ-5D-5L™ before and after operation
Unilateral Bilateral
One-stage IBBR+ADM
(n=27)
Two-stage IBBR
(n=32) P*
One-stage IBBR+ADM
(n=32)
Two-stage IBBR
(n= 30) P*
Preoperative
EQ-5D-5L™ score 0⋅78(0⋅17) (n= 17) 0⋅86(0⋅12) (n= 17) 0⋅93(0⋅08) (n= 15) 0⋅86(0⋅14) (n= 14)
EQ-VAS (0–100) 69⋅0(17⋅4) (n= 17) 78⋅8(17⋅9) (n= 17) 89⋅0(9⋅6) (n= 15) 74⋅9(11⋅2) (n= 14)
Postoperative
EQ-5D-5L™ score 0⋅89(0⋅08) (n= 22) 0⋅93(0⋅10) (n= 24) 0⋅220 0⋅92(0⋅11) (n= 26) 0⋅93(0⋅08) (n= 20) 0⋅648
EQ-VAS (0–100) 79⋅7(12⋅9) (n= 20) 79⋅9(14⋅8) (n= 18) 0⋅967 85⋅4(11⋅5) (n= 25) 82⋅3(9⋅4) (n= 17) 0⋅354
Values are mean(s.d.). IBBR, implant-based breast reconstruction; ADM, acellular dermal matrix. *Student’s t test.
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respectively; P= 0⋅025) and bilateral (€16 939 (14 887
to 19 360) versus €13 383 (12 414 to 14 669); P = 0⋅002)
procedures.
Health outcomes
The EQ-5D-5L™ questionnaire was completed before
operation by 63 patients (52⋅1 per cent) and after surgery
by 92 patients (76⋅0 per cent). Mean(s.d.) scores were
0⋅86(0⋅14) and 0⋅92(0⋅10) respectively. In general, scores
were higher after operation in all groups (Table 6). There
were no significant differences between postoperative
EQ-5D-5L™ or EQ-VAS scores between one-stage IBBR
with ADM and two-stage IBBR for both unilateral and
bilateral reconstructions.
Discussion
This RCT could not confirm the hypothesis that
ADM-assisted one-stage IBBR is more cost-effective
than two-stage IBBR. The direct costs of one-stage IBBR
with ADM were higher than those of two-stage recon-
struction, and health outcomes did not differ between
the groups.
The way in which healthcare is financed differs con-
siderably between countries and healthcare costs can be
calculated from various viewpoints. In the Netherlands, all
citizens have mandatory health insurance, which is partly
sponsored by the government. Reimbursement by health
insurers is based on Diagnosis Related Groups (DRGs)
using average costing; therefore, reimbursement amounts
do not reflect actual costs of specific procedures, similar to
payment systems in many other countries. This implies that
the sum reimbursed is payable regardless of the actual costs
to the hospital providing the relevant care. When compar-
ing the costs of breast reconstruction with and without the
additional use of ADM, it seems inappropriate to use reim-
bursement amounts as these do not reflect the actual costs
associated with its use. Even if the costs of ADMs were
reimbursed separately, this may not reflect the actual costs.
For example, Krishan and colleagues11 reported that a large
discrepancy exists between the actual cost of an ADM
(US $4890; €4278, exchange rate 2 January 2019) and its
reimbursement ($214⋅10; €187⋅31). Therefore, costs were
calculated from a hospital perspective in the present study.
This way of calculating costs is not without problems, how-
ever, as costs may differ considerably across institutions;
costs of overheads, implants, personnel required, financing
strategies and private interests can all vary. For this reason,
the data for underlying variables were also reported (such
as duration of operation time and hospital stay) to enable
comparison with other studies and to allow cost calcula-
tions using different tariffs.
The results indicate that, from an institutional perspec-
tive, costs of one-stage IBBR with ADM reconstruction
are higher than those of two-stage reconstruction, whereas
reimbursement for the one-stage reconstruction is lower.
This was true when the primary procedure alone was taken
into account. The difference in costs between the two
methods increased when the costs of additional procedures
to treat surgical complications were also included. The
major factors contributing to this difference were the price
of the implant material and costs related to a higher com-
plication rate.
Previous authors have used a mixture of perspectives to
estimate costs, such as a third-party payer perspective with
supplementary costs of ADM included in the calculations.
Only a few studies13–15,25 have reported on costs of ADMs
in one-stage implant-based breast reconstruction. None
of these analyses was based on prospectively collected
data, but costs were derived theoretically by adopting a
third-party payer perspective, and analyses usually included
data from literature reviews to estimate complication rates.
Using this method, de Blacam and co-workers14 compared
one-stage IBBR versus ADM with two-stage IBBR with and
without ADM. ADM-assisted one-stage IBBR was the least
expensive approach; this was still the case if the incremen-
tal costs of complications were included. The probability of
complications was based on previously published literature.
However, when an ADM was used, the authors adjusted
for the extended duration of operation only and did not
include the material costs of ADM. The authors noted
that Medicare reimbursement of breast reconstruction with
ADM is erroneously low, that the relative increase in cost
incurred by the use of ADM is substantial when extrapo-
lated nationwide, and that the excess costs associated with
ADMs are amplified by the higher incidence of complica-
tions associated with their use. Johnson et al.13 also com-
pared ADM-assisted one-stage IBBR with conventional
two-stage IBBR. They used retrospective data from 24
patients in the one-stage and 22 in the two-stage group to
assess surgery-related variables and complications. Cost-
ings were based on the tariffs governing reimbursement
in the National Health Service in England, and the actual
costs of ADM were added to the cost calculations. In
contrast to actual costs, tariffs in England are the same for
unilateral and bilateral procedures, giving a rather skewed
picture, where one-stage IBBR seemed less costly than
two-stage IBBR in unilateral procedures, but more costly
in bilateral procedures. In another retrospective cohort
study25, no significant cost differences between two-stage
IBBR and one-stage ADM-assisted IBBR were reported,
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but details regarding the perspective and methods to cal-
culate costs were lacking. In a Canadian study15, costs of
direct-to-implant reconstruction with AlloDerm® (Life-
Cell, Branchburg, New Jersey, USA) were compared with
two-stage non-AlloDerm® reconstruction. The payment
system in Canada is not based on DRGs, and costs from
the third-party payer perspective corresponded closely to
direct costs from the hospital perspective. Expected costs
were calculated by means of a decision analytical model
using data from previous studies. Based on similar com-
plication rates in both groups and an assumed 10 per cent
lower capsular contraction rate in the one-stage group,
expected costs of one-stage reconstruction were lower.
Total costs were sensitive to the price of the ADM and
duration of operation; it was shown that variation in these
factors may tip the balance of cost advantage between the
two procedures.
ADMs are relatively expensive, with reported prices of
biological ADMs varying from £1292 (€1433, exchange
rate 2 January 2019) to £4890 (€5425)11,13–15. In the
present study in a Dutch hospital setting, the costs of
an ADM in a one-stage procedure outweighed the costs
of additional duration of surgery in a two-stage proced-
ure. With costs of the implant material and overall dur-
ation of surgery time being the primary differentiating cost
drivers, the costs of one ADM (€2370) corresponded to
those of over 1⋅5 h of surgery (including surgeon’s fee).
Less expensive alternatives to ADMs have, however, been
introduced. One example is the TiLOOP® Bra (pfm med-
ical, Cologne, Germany), a titanized mesh. However, the
effectiveness and safety of each of these products have to
be evaluated. A small RCT26 comparing TiLOOP® with
another porcine ADM, Protexa® (Tecnos, Turin, Italy),
showed a higher severe complication rate with implant loss
in the Protexa® group. Larger studies are needed to con-
firm these results and demonstrate cost-effectiveness.
A more costly procedure may be justifiable if it creates
more value for the patient. To assess whether a procedure
is cost-effective, it is necessary to determine its actual costs
and value with regard to health outcomes. It has been
suggested that the use of ADM in breast reconstruction
gives aesthetically better results and that it reduces capsular
contracture rates. For instance, Krishan and colleagues12
concluded that the use of ADMs in two-stage IBBR was
cost-effective despite higher costs and a higher complica-
tion rate in ADM-assisted IBBR. This was based on the
assumption that quality of life is better in women treated
with ADMs, resulting in higher quality-adjusted life-years
(QALYs). However, this assumption was not based on
patient-reported outcomes, but on the expert opinion of
plastic surgeons. Actual data on health-related quality of
life after one-stage IBBR with and without use of ADM
were lacking17. In the present study, patient-reported
health status assessed using the EQ-5D-5L™ was no
different between groups. Furthermore, there was no
difference between groups in specific patient-reported
outcomes regarding quality of life and satisfaction27. Based
on these outcomes at 1 year after definite placement of
the breast implant, there was no indication of differences
in QALYs between the two groups. Therefore, this study
cannot confirm that one-stage ADM-assisted IBBR is
more cost-effective than two-stage IBBR. Health status
improved after the reconstruction, with postoperative
EQ-5D™ index values being higher than preoperative
values. Remarkably, postoperative scores in the present
study were also higher than reference values for the Dutch
general population (mean(s.d.) for women 0⋅86(0⋅17))24,
indicating the importance of postmastectomy breast
reconstruction in restoring emotional health and
self-esteem.
This is the first randomized study to compare both costs
and health status between ADM-assisted one-stage IBBR
and two-stage IBBR. To deal with the unknown distribu-
tion of cost for this type of surgery, estimation of costs
was done using bootstrapping and no further assumptions
were made in the comparison. The study, however, has
several limitations. Costs were calculated from an insti-
tutional perspective. Direct costs may vary considerably
between institutions, and should be reassessed for different
settings. Furthermore, socioeconomic costs were not taken
into account. The impact on patients was addressed only
partly by the EQ-5D-5L™ questionnaire. Social implica-
tions and consequences of multiple operations, resulting
in patient burden, absence from work and travel expenses,
were not measured. It may be argued that the impact of
a two-stage reconstruction is greater owing to multiple
outpatient visits for filling of the expander and a second
operation. This applies only to an uneventful postopera-
tive course. In the present study, it was noted that mul-
tiple additional procedures were carried out, especially in
the one-stage group owing to a much higher complication
rate. The specific burden of these treatments was not con-
sidered in the cost analyses. Future studies are needed to
address this issue. Another limitation is that the trial had a
relatively small sample size and not all women completed
the EQ-5D-5L™, which reduced the statistical power of
the analyses. Finally, follow-up was too short to assess pos-
sible differences in capsular contracture rates.
With similar health outcomes and increased costs,
ADM-assisted one-stage IBBR was not cost-effective rel-
ative to two-stage IBBR. The additional costs of ADM in
ADM-assisted one-stage IBBR and increased costs related
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to higher complication rates exceeded the costs saved by
reduced operating times.
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